Farxiga Cost in Oklahoma (2026): Dapagliflozin Prices, Insurance, and Savings

What Does Farxiga Actually Cost in Oklahoma Right Now?

The average cash-pay price for brand-name Farxiga at Oklahoma retail pharmacies in 2026 sits at roughly $620 per month for a 30-day supply of 10 mg tablets. This figure tracks closely with AstraZeneca's national list price and has remained relatively stable over the past year. Without insurance or discount programs, this is what most Oklahomans will see at the pharmacy counter.

That $620 figure represents the wholesale acquisition cost passed through to retail. Actual prices vary by pharmacy. Costco and independent pharmacies in the Oklahoma City and Tulsa metro areas sometimes price 5 to 8 percent below chain competitors for cash-pay customers. Mail-order pharmacies, including those affiliated with the three largest PBMs (CVS Caremark, Express Scripts, and OptumRx), may offer 90-day supplies at a modest per-unit discount 1.

The SGLT2 inhibitor class, which includes dapagliflozin, empagliflozin (Jardiance), and canagliflozin (Invokana), carries similar pricing nationwide. A 2023 analysis published in Diabetes Care found that out-of-pocket costs for SGLT2 inhibitors averaged $150 to $300 per month for commercially insured patients before manufacturer coupons, with wide variation depending on formulary tier 2.

Price-comparison tools like GoodRx and RxSaver show Oklahoma-specific pricing. These platforms aggregate discount card offers that can reduce cash-pay costs by 10 to 25 percent at participating pharmacies, though the final price still typically exceeds $400 per month without additional manufacturer support.

Does Oklahoma Medicaid Cover Farxiga?

Oklahoma Medicaid does not cover Farxiga as of 2026. This applies to both fee-for-service Medicaid and the state's managed care programs administered through SoonerSelect.

Oklahoma expanded Medicaid under the Affordable Care Act in 2021, adding roughly 300,000 new enrollees. The state's preferred drug list (PDL), maintained by the Oklahoma Health Care Authority (OHCA), does not include dapagliflozin among covered SGLT2 inhibitors. Prescribers can submit a prior authorization request through the state's clinical criteria process, but approvals for non-PDL medications require documented failure of preferred alternatives 3.

This gap matters clinically. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001), with benefits observed regardless of diabetes status 3. For Oklahoma Medicaid patients with heart failure, the absence of coverage creates a barrier to a therapy with strong guideline support.

The American College of Cardiology and the American Heart Association's 2022 guideline update for heart failure management gives SGLT2 inhibitors a Class I recommendation for patients with HFrEF 4. Dr. Clyde Yancy, past president of the AHA, stated: "SGLT2 inhibitors represent a new pillar of heart failure therapy that should be accessible to all patients regardless of payer status" 4.

Oklahoma Medicaid patients who need dapagliflozin have several options: request prior authorization through the prescriber, apply for AstraZeneca's patient assistance program (which covers uninsured and underinsured patients), or explore compounded alternatives through 503A pharmacies.

How the AstraZeneca Savings Card Works in Oklahoma

AstraZeneca offers a manufacturer savings card for Farxiga that can reduce copays to $0 per month for eligible commercially insured patients. The program has no income requirement for those with commercial insurance.

Eligibility requires active commercial or private insurance that covers Farxiga. Patients on Medicare, Medicaid, Tricare, or other federal or state government programs do not qualify. The savings card covers up to $175 per 30-day fill, with the card making up the difference between the patient's copay and $0.

Enrollment is straightforward. Patients can register online through AstraZeneca's Farxiga savings portal, by calling the support line, or through their prescriber's office. The card is reusable for up to 12 months and renewable annually. Oklahoma pharmacies process the card as a secondary insurance claim at the point of sale.

For patients without any insurance, AstraZeneca's separate Patient Assistance Program (AZ&Me) provides Farxiga at no cost to qualifying individuals. Income eligibility thresholds are set at 400% of the federal poverty level, which in 2026 translates to approximately $62,400 for a single individual or $129,000 for a family of four 1. Application requires proof of income and a signed prescription from a licensed provider.

Which Oklahoma Insurance Plans Cover Farxiga?

Most major commercial health plans operating in Oklahoma cover dapagliflozin, though formulary placement and cost-sharing vary. Plans from Blue Cross Blue Shield of Oklahoma, UnitedHealthcare, Aetna, and Cigna generally include Farxiga on their formularies, often at Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific plan design.

Tier placement determines copay. A Tier 3 placement typically carries a $40 to $75 copay per fill. Tier 4 may require coinsurance of 25 to 40 percent, pushing monthly costs to $150 or more before savings card application. Patients should check their specific plan's formulary, as employer-sponsored plans negotiate their own drug lists separately from individual market plans.

Prior authorization is common across Oklahoma insurers for SGLT2 inhibitors. The typical clinical criteria require a diagnosis of type 2 diabetes with documented HbA1c above target despite metformin, or a diagnosis of heart failure (NYHA Class II-IV) or chronic kidney disease (eGFR 25 to 75 mL/min/1.73 m²) 5.

The clinical case for coverage has strengthened since the DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite endpoint of sustained decline in eGFR of 50% or more, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) 5. This trial, published in the New England Journal of Medicine in 2020, led the FDA to expand Farxiga's indication to include chronic kidney disease regardless of diabetes status.

Oklahoma Health Insurance Marketplace plans sold through healthcare.gov follow similar formulary structures. Patients selecting plans during open enrollment should compare formulary tiers and total annual drug costs, not just monthly premiums, to identify the most cost-effective option for ongoing dapagliflozin therapy.

Is Compounded Dapagliflozin Legal in Oklahoma?

Compounded dapagliflozin is available in Oklahoma through licensed 503A compounding pharmacies. State law permits 503A pharmacies to compound medications based on individual patient prescriptions from licensed prescribers.

A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies compound medications in response to a specific prescription for an identified patient, as distinct from 503B outsourcing facilities that produce larger batches without individual prescriptions 6. Oklahoma's Board of Pharmacy licenses and inspects 503A facilities operating within the state.

The cost difference is significant. Compounded dapagliflozin from 503A pharmacies can cost substantially less than brand-name Farxiga. Several Oklahoma-based compounding pharmacies and multistate 503A operations offer dapagliflozin formulations.

There are considerations. Compounded drugs are not FDA-approved products. They do not undergo the same manufacturing standards, bioequivalence testing, or stability studies as branded pharmaceuticals. The FDA's guidance document on compounding states that compounded products "are not evaluated for safety, efficacy, or manufacturing quality before they are marketed" 6.

Patients considering compounded dapagliflozin should verify that the pharmacy holds an active Oklahoma Board of Pharmacy license, ask about third-party potency and sterility testing, and discuss the option with their prescribing physician. Some clinicians prefer brand-name Farxiga for its established bioavailability profile; others find compounded versions a reasonable option when cost prevents adherence.

Can You Get Farxiga Via Telehealth in Oklahoma?

Yes. Oklahoma law permits telehealth prescribing of Farxiga, and multiple telehealth platforms operating in the state include SGLT2 inhibitors in their prescribing formularies.

Oklahoma's telehealth regulations, codified under the Oklahoma Telemedicine Act, allow physicians and advanced practice providers licensed in Oklahoma to prescribe medications via audio-video consultations. A pre-existing in-person relationship is not required for prescribing in most clinical scenarios. Dapagliflozin, as a non-controlled substance, faces no additional telehealth prescribing restrictions 7.

Telehealth visits for dapagliflozin initiation typically include review of recent lab work (HbA1c, eGFR, serum potassium), assessment of current medications for interactions, and baseline blood pressure measurement. The DECLARE-TIMI 58 trial (N=17,160), published in the New England Journal of Medicine, demonstrated the cardiovascular safety profile that supports prescribing dapagliflozin across a broad type 2 diabetes population, with a 17% reduction in cardiovascular death or hospitalization for heart failure (HR 0.83 to 95% CI 0.73 to 0.95, P=0.005) 7.

Dr. Mikhail Kosiborod, cardiologist at Saint Luke's Mid America Heart Institute, has noted: "The totality of evidence for SGLT2 inhibitors across diabetes, heart failure, and kidney disease makes them among the most impactful cardiovascular drugs developed in the last two decades" 3.

Rural Oklahomans stand to benefit most from telehealth access. Thirty-three of Oklahoma's 77 counties are designated health professional shortage areas for primary care. Telehealth eliminates the geographic barrier for patients in these counties who might otherwise drive hours to see an endocrinologist or cardiologist.

Practical Steps to Lower Your Farxiga Cost in Oklahoma

Reducing out-of-pocket dapagliflozin costs in Oklahoma requires a layered approach. No single strategy works for every patient, but combining two or three typically brings costs well below $620 per month.

Step 1: Check your formulary. Call the number on the back of your insurance card and ask whether dapagliflozin (Farxiga) is on your plan's formulary and at which tier. Request the prior authorization criteria if the drug requires it.

Step 2: Apply the AstraZeneca savings card. If you have commercial insurance, register for the manufacturer savings card before your next fill. The card processes automatically at the pharmacy and can reduce your copay to $0 1.

Step 3: Explore patient assistance. If you are uninsured or on a government plan (other than Medicare Part D), apply for AstraZeneca's AZ&Me program. Processing takes 4 to 6 weeks, so plan ahead.

Step 4: Compare pharmacy prices. Oklahoma pharmacy prices vary. Use GoodRx, RxSaver, or call pharmacies directly. Costco pharmacies do not require a membership for prescription purchases in Oklahoma.

Step 5: Ask about compounded dapagliflozin. If brand-name pricing remains prohibitive, discuss compounded options with your prescriber. Confirm the compounding pharmacy is licensed by the Oklahoma Board of Pharmacy.

Step 6: Consider 90-day fills. Many insurance plans and discount programs offer reduced per-unit pricing on 90-day supplies. Mail-order pharmacies commonly provide this option.

The 2024 AHA/ACC/HFSA joint committee highlighted that medication cost remains a top contributor to non-adherence in heart failure, with SGLT2 inhibitors filling rates dropping significantly when monthly out-of-pocket costs exceed $50 4. Proactive cost reduction is not just financial planning. It directly affects clinical outcomes.

Oklahoma-Specific Discount and Assistance Programs

Beyond manufacturer programs, several Oklahoma-based resources can help offset Farxiga costs.

The Oklahoma Drug Assistance Program, operated through the OHCA, provides limited medication assistance for residents who do not qualify for Medicaid but cannot afford medications. Eligibility criteria include Oklahoma residency, income below 200% of the federal poverty level, and no prescription drug coverage 8.

Federally Qualified Health Centers (FQHCs) in Oklahoma participate in the 340B Drug Pricing Program, which allows these facilities to purchase outpatient drugs at significantly reduced prices. Oklahoma has over 20 FQHC organizations with more than 90 sites statewide. Patients seen at 340B-eligible facilities may access Farxiga at substantially lower cost, sometimes at a flat dispensing fee regardless of drug acquisition cost.

Nonprofit patient assistance foundations, including the Patient Access Network (PAN) Foundation and the HealthWell Foundation, periodically open funding cycles for SGLT2 inhibitors. These programs serve patients with Medicare or commercial insurance whose copays exceed a threshold, typically $50 per month. Availability fluctuates based on donor funding, so patients should check eligibility regularly.

Oklahoma's diabetes burden makes these programs particularly relevant. The CDC's 2023 data showed that 12.7% of Oklahoma adults had diagnosed diabetes, ranking the state among the top 10 nationally 8. The state's uninsured rate, despite Medicaid expansion, remains above the national average at approximately 14%.

Dapagliflozin Dosing, Monitoring, and What Oklahoma Prescribers Need to Know

Dapagliflozin is dosed at 10 mg once daily for all three FDA-approved indications: type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. The 5 mg starting dose, previously used in diabetes, has been simplified to a single 10 mg dose across indications per the updated FDA label 1.

Baseline labs before initiation should include eGFR, serum potassium, HbA1c (for diabetic patients), and a urinalysis. Repeat eGFR at 1 to 3 months after starting, then at least annually. An initial eGFR dip of 10 to 15% is expected and should not prompt discontinuation. The DAPA-CKD trial confirmed that this early dip reversed, and long-term eGFR decline was slower with dapagliflozin versus placebo 5.

Key safety considerations for Oklahoma prescribers include genital mycotic infections (occurring in approximately 5 to 7% of patients), volume depletion risk in patients on loop diuretics, and the rare but serious risk of euglycemic diabetic ketoacidosis, particularly in patients with type 1 diabetes (an off-label use the FDA label warns against) 1.

Dapagliflozin should not be initiated when eGFR falls below 25 mL/min/1.73 m², but patients already taking the drug can continue until dialysis or transplant. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guideline reinforced SGLT2 inhibitors as first-line therapy alongside renin-angiotensin system blockade for CKD patients with albuminuria 9.

Prescribers should counsel patients to maintain hydration, report any symptoms of genital infection promptly, and hold dapagliflozin during acute illness or perioperatively to reduce ketoacidosis risk. Routine A1c monitoring every 3 to 6 months applies for diabetic patients, while heart failure patients benefit from periodic NT-proBNP measurement to track treatment response.